Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME
Abstract Management of vitreoretinal disorders (e.g., neovascular age-related macular degeneration [nAMD] and diabetic macular edema [DME]) have assumed the standard therapy of lifelong anti-VEGF injections with drugs like aflibercept, brolucizumab, ranibizumab and bevacizumab. However, the burden i...
| Main Authors: | , , , , , , , , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
BMC
2024-01-01
|
| 丛编: | International Journal of Retina and Vitreous |
| 主题: | |
| 在线阅读: | https://doi.org/10.1186/s40942-024-00525-9 |